Tag: Hatch-Waxman Act
-
25 May
-
18 May
Authorized Generics Market Outlook: Strategy, Trends & Future Role (2026)
Explore the future role of authorized generics in the pharmaceutical market. We analyze strategic timing, regulatory shifts like the FDA's 2025 pilot program, and the impact on drug pricing and competition. -
13 May
Why Generic Medications Cost Less: The Truth Behind the Savings
Discover why generic medications cost significantly less than brand-name drugs. Learn about the Hatch-Waxman Act, market competition, and hidden costs like spread pricing. Find practical tips to maximize your healthcare savings today. -
18 Feb
FDA’s Abbreviated New Drug Application Process Explained: How Generic Drugs Get Approved
The FDA's ANDA process lets generic drugs reach the market faster and cheaper by proving they're bioequivalent to brand-name drugs. It's saved U.S. patients $373 billion since 2021 and powers 90% of prescriptions. -
23 Jan
180-Day Exclusivity: How Patent Law Controls Generic Drug Market Entry
The 180-day exclusivity rule under the Hatch-Waxman Act gives the first generic drug maker to challenge a patent a temporary monopoly, delaying competition and keeping prices high. Here’s how it works-and why it’s broken. -
4 Dec
Paragraph IV Certifications: How Generic Drug Makers Challenge Patents Before Launch
Paragraph IV certifications let generic drug makers challenge brand patents before launch, speeding up affordable drug access. This legal tool under the Hatch-Waxman Act saves billions annually but faces challenges from patent thickets and pay-for-delay deals.
- Recent
- Popular
